Showing 1121-1130 of 1635 results for "".
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- New Report Calls for a National Eye Care Plan for England to Address Surging Patient Demandhttps://modernod.com/news/new-report-calls-for-a-national-eye-care-plan-for-england-to-address-surging-patient-demand/2482003/As part of Westminster Eye Health Day, stakeholders and experts from across the eye health sector have launched a new report laying out action required to improve eye care for patients in England. The initiative is led by "The Eyes Have It," a partnership of Macular Society, Fight
- NORA Names New Executive and Advisory Board Membershttps://modernod.com/news/nora-names-new-executive-and-advisory-board-members/2481983/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the appointments of its new Executive and Advisory Board members. NORA is an interdisciplinary group of professionals dedicated to providing a complete ocular health evaluation and optimum visual rehabilitation educat
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-